A Research Study on How NNC0638-0355, a New Medicine, Works in People Living With Overweight or Obesity

September 29, 2026 updated by: Novo Nordisk A/S

A Randomised, Placebo Controlled, Double Blinded Study Assessing the Safety, Tolerability and Pharmacokinetics of Single and Multiple Subcutaneous Doses of NNC0638-0355 in Participants With Overweight or Obesity

The study is testing a new study medicine to treat people living with overweight or obesity. The aim of this study is to see if the medicine is safe, how it works in your body, and what your body does to the study medicine. Participants will either get the study medicine or placebo (a "dummy medicine" similar to the study medicine but without active ingredients) given as an injection under your skin. Which treatment the participants get is decided by chance. The study medicine is a potential new medicine which cannot be prescribed by doctors.

Study Overview

Status

Active, not recruiting

Conditions

Study Type

Interventional

Enrollment (Actual)

63

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Groningen, Netherlands, 9728 NZ
        • ICON - location Groningen
    • Kansas
      • Lenexa, Kansas, United States, 66219
        • ICON Early Phase Services, LLC
    • Texas
      • San Antonio, Texas, United States, 78209
        • ICON
    • Utah
      • Salt Lake City, Utah, United States, 84124
        • ICON-Salt Lake City

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 55 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Key inclusion criteria

  • Male or female.
  • Age 18-55 years (both inclusive) at the time of signing the informed consent.
  • BMI between 25.0 and 34.9 kg/m^2 (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator.
  • Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Key exclusion criteria

  • Known or suspected hypersensitivity to study intervention(s) or related products.

  • Any condition, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.

  • HbA1c greater than or equal to 6.5 percentage (48 mmol/mol) at screening.

  • Any laboratory safety parameters at screening outside the below laboratory ranges, see designated reference range documents for specific values:

    1. Vitamin D (25-hydroxycholecalciferol) less than 12 ng/mL (30 nM) at screening
    2. Parathyroid hormone (PTH) outside normal range at screening
    3. Total calcium outside normal range at screening

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: NNC0638-0355

Participants will be randomized to receive NNC0638-0355. The study will be conducted in 5 parts. Part A: Single ascending dose (SAD) Part B, C, D and E: Multiple ascending dose (MAD).

NNC0638-0355 will be administered as a subcutaneous (s.c. under the skin) injection.

Placebo Comparator: Placebo

Participants will be randomized to receive Placebo. The study will be conducted in 5 parts. Part A: Single ascending dose (SAD). Part B, C,D and E: Multiple ascending dose (MAD).

Placebo matching NNC0638-0355 will be administered as subcutaneous (s.c. under the skin) injection.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Part A: Number of treatment emergent adverse events (TEAE)
Time Frame: From NNC0638-0355 administration (day 1) to completion of the end of study visit (6 weeks)

Measured as Number of events

From NNC0638-0355 administration (day 1) to completion of the end of study visit (6 weeks)
Part B,C,D and E : Number of treatment emergent adverse events (TEAE)
Time Frame: From first NNC0638-0355 administration (day 1) to completion of the end of study visit (20 weeks)

Measured as Number of events

From first NNC0638-0355 administration (day 1) to completion of the end of study visit (20 weeks)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Part A: AUC; area under the NNC0638-0355 plasma concentration-time curve
Time Frame: From NNC0638-0355 administration (day 1) to completionof the end of study visit (6 weeks)

Measured in hours*nano mole per litre (h*nmol/L)

From NNC0638-0355 administration (day 1) to completionof the end of study visit (6 weeks)
Part A: Cmax; maximum observed NNC0638-0355 plasma concentration
Time Frame: From NNC0638-0355 administration (day 1) to completionof the end of study visit (6 weeks)

Measured in nano mole per litre (nmol/L)

From NNC0638-0355 administration (day 1) to completionof the end of study visit (6 weeks)
Part B,C,D and E: AUC; area under the NNC0638-0355 plasma concentration-time curve
Time Frame: From first NNC0638-0355 administration (day 1) to completionof the end of study visit (20 weeks)

Measured in hour*nano mole per litre (h*nmol/L)

From first NNC0638-0355 administration (day 1) to completionof the end of study visit (20 weeks)
Part B,C,D and E: Cmax; maximum observed NNC0638-0355 plasma concentration
Time Frame: From first NNC0638-0355 administration (day 1) to completionof the end of study visit (20 weeks)

Measured in nano mole per litre (nmol/L)

From first NNC0638-0355 administration (day 1) to completionof the end of study visit (20 weeks)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Clinical Transparency (dept. 2834), Novo Nordisk A/S

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 3, 2024

Primary Completion (Estimated)

October 11, 2027

Study Completion (Estimated)

October 11, 2027

Study Registration Dates

First Submitted

August 28, 2024

First Submitted That Met QC Criteria

August 28, 2024

First Posted (Actual)

August 29, 2024

Study Record Updates

Last Update Posted (Actual)

September 30, 2026

Last Update Submitted That Met QC Criteria

September 29, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • NN9638-7569
  • U1111-1296-8015 (Other Identifier: World Health Organization (WHO))

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe